Non-alcoholic fatty liver disease (NAFLD) is a broad term used to cover a spectrum of conditions which are characterized by evidence of hepatic steatosis on imaging or histology (macro-vesicular steatosis), and absence of secondary causes of hepatic steatosis such as significant alcohol consumption, chronic use of medications that can cause hepatic steatosis, or hereditary disorders. The definition of significant alcohol consumption has not been consistent, and for NASH clinical trials it has been defined as ongoing or recent consumption of more than 14 standard drinks on average per week in women and more than 21 standard drinks on average per week in men. Non-alcoholic fatty liver disease is most often diagnosed incidentally on imaging or when it presents with complications. The prevalence of NAFLD in western countries is around 20 to 30 %. NAFLD is considered to be the liver manifestation of metabolic syndrome. 50 to 70% of people with diabetes are found to have NAFLD.
NAFLD has several phases of progression which include simple steatosis, steatohepatitis, fibrosis, cirrhosis and ultimately could even progress to hepatocellular carcinoma. The disease has a benign course; it is a silent liver disease when the only histological finding is steatosis. The presence of hepatic injury with inflammation with or without fibrosis constitutes non-alcoholic steatohepatitis (NASH). Please refer to the chapters on hepatitis, nonalcoholic steatohepatitis under transplant hepatology section for a detailed discussion of this topic.
Obesity, diabetes, dyslipidemias, insulin resistance and metabolic syndrome are known to be associated with the development of non-alcoholic fatty liver disease. A temporal association has also been shown between inorganic arsenic exposure and the development of NAFLD reflected by elevated alanine transferase (ALT). Due to its close association with metabolic syndrome, NAFLD correlates with cardiovascular risk factors which also contributes to mortality in these patients in addition to end-stage liver cirrhosis and hepatocellular carcinoma.
Non-alcoholic fatty liver disease (NAFLD) incidence is rapidly increasing especially in Western countries. Increasing obesity levels, increasing incidence of childhood obesity, sedentary lifestyles, consumption of unhealthy quick eats, and a longer lifespan are some of the likely contributors. The incidence and prevalence of NAFLD are underestimated as ultrasonography is commonly used to screen for fatty liver disease. The prevalence of NAFLD is 80 to 90% in obese adults, 30 to 50% in patients with diabetes mellitus, 90% or more in patients with hyperlipidemia, 3 to 10% in children and as high as 40 to 70% among obese children.
Both environmental and genetic factors are contributing factors in the development of non-alcoholic fatty liver disease and its progression. First-degree relatives of patients with NAFLD are at higher risk than the general population. Histone amino-terminal ends, maintain the chromatin structure and gene expression that is cAMP-responsive element binding protein H (CREBH) or SIRT1. Genetic studies have shown that activation of SIRT1 is thought to play a role in the development of NAFLD. The trigger of the progression of NAFLD to cancer is via abnormal DNA methylation.
Day and James proposed a two-hit model of pathogenesis in 1998. The first hit is caused by insulin resistance which leads to accumulation of fat droplets that is triglycerides in the cytoplasm of hepatocytes leading to the development of steatosis. Insulin resistance causes excess delivery of free fatty acid and triglycerides to the liver and decreased excretion leading to accumulation. Also, excess carbohydrates are also a stimulus for de no fatty acid synthesis in the liver
The second hit causing hepatocellular injury and the development of NASH is multifactorial. Excessive fatty acids in the liver make the liver more vulnerable to injury. Peroxisomal fatty acid oxidation, ROS production from the mitochondrial respiratory chain, cytochrome P450 metabolism of fatty acids, hepatic metabolism of gut-derived alcohol is hypothesized to cause the injury. Obesity also contributes to the second hit as adipose tissue releases inflammatory mediators such as leptin, TNF- alpha and IL-6 causing hepatocyte damage. The hepatocytes undergo ballooning, cytoskeletal aggregation, apoptosis, and necrosis.
Insulin resistance is also a part of the second hit. The sinusoidal collagen deposition caused by the activation of hepatic stellate cells and the portal fibrosis caused by the ductular proliferation leads to the development and progression of NASH. These changes have correlated with insulin resistance which is now believed to cause the progression of steatosis to NASH and progressive fibrosis.
Non-alcoholic fatty liver disease is more than 10 % of hepatocytes with fat droplets on liver biopsy. Functionally, the liver subdivides into 3 zones; the classification is made based on the oxygen supply. Zone 1 has the highest oxygenation (oxygenated blood from hepatic arteries) and encircles the portal tracts, and Zone 3 encircles the central veins where the oxygenation is poor.
American Association for the Study of Liver Diseases (AASLD) defined the histopathological abnormalities required in the diagnosis of NASH which includes steatosis (macro more than micro), lobular inflammation and hepatocellular ballooning is seen most apparently in the zone 3 steatotic liver cells. Fibrosis, although not necessary for the diagnosis is usually present. Some other findings seen are Mallory-Denk bodies (MDB, eosinophilic intracytoplasmic inclusions), megamitochondria, glycogenated nuclei, and iron deposition.
Fibrosis starts in the acinar zone 3 and has the appearance of chicken wire from the deposition of collagen and other extracellular matrices along the sinusoids. NASH-related cirrhosis is macronodular or mixed. When cirrhosis develops the other histological features may not be evident.
Patients with non-alcoholic fatty liver disease could present with many non-specific symptoms way before the diagnosis is made although most patients are asymptomatic. Fatigue is one of the most common presenting symptoms. Sharp or dull aching upper abdominal pain, thirst, bloating and sleep disturbances. Patients who develop NASH-associated cirrhosis, end-stage liver disease or HCC present with symptoms like:
The most common clinical sign is mild to moderate hepatomegaly. Advanced stages of the spectrum can demonstrate signs of end-stage liver disease such as:
Mildly elevated serum aminotransferases are the primary abnormality in non-alcoholic fatty liver disease although the liver enzymes are normal in the majority of patients. The ratio of AST to ALT is less than 1. GGT, when elevated in NAFLD, can be a marker of increased mortality. With the progression of the disease hypoalbuminemia, hyperbilirubinemia, thrombocytopenia and prolonged prothrombin time present due to hepatic synthetic dysfunction.
Ultrasound of the abdomen is routinely used to evaluate for fatty liver, but a liver biopsy is considered the gold standard for the diagnosis of NAFLD. A non-invasive clinical scoring system called NAFLD-MS score was developed to predict the development of NAFLD in patients with metabolic syndrome. The clinical predictors included are BMI greater than or equal to 25, AST/ALT greater than or equal to 1, type 2 diabetes mellitus and obesity. The positive likelihood ratio of developing NAFLD is 2.32 (low when the score is less than 3), and the risk is 7.77 (high when the 5 or more). Some of the other scoring systems are NAFLD fibrosis score (NFS), FIB-4 (Fibrosis-4) Index, original ELF test, AST-to-platelet ratio index (APRI), AAR, FibroMeter, NAFLD-MS score.
Lifestyle changes are recommended for all patients with non-alcoholic fatty liver disease even without NASH as these patients have metabolic derangements and are at risk for the development of cardiovascular diseases. A weight loss of 3 to 5% in simple steatosis and a weight loss of 7 to 10% in NASH is the recommendation. Adequate control of risk factors like hyperlipidemia with statins (it also protects from cardiovascular risks), hypertension, adequate glycemic control is required. Please refer to the chapters on hepatitis, nonalcoholic steatohepatitis under transplant hepatology section for a detailed discussion of this topic.
Patients with NASH are to followed by hepatologists or gastroenterologists. NASH with cirrhosis require hepatocellular carcinoma surveillance with an ultrasound every 6 months. Several clinical trials are being conducted using anti-fibrotic, anti-apoptotic, and immune therapies for the treatment of NAFLD.
The differential diagnosis of non-alcoholic fatty liver disease (conditions that can also cause hepatic steatosis) include:
Patients with non-alcoholic fatty liver disease exhibit increased mortality rates when compared to the general population. These patients have a high risk of mortality from cardiovascular causes as these patients have metabolic derangements. Cardiovascular causes of mortality are higher in these patients over liver causes. NAFLD is a slowly progressive disease; simple steatosis is reversible and non-progressive whereas NASH can progress to cirrhosis. Over a 13 year follow up, the progression of cirrhosis presented in 41% in a study done by Ekstedt et al. A meta-analysis was done by White et al., showed that in cohorts of NADLF or NASH with few or no cases of cirrhosis the risk of developing HCC was minimal at 0 to 3% over 20 years and in cohorts with NASH with cirrhosis the risk was high at 2.4 % over 7 years.
The most important complications in the descending order are cardiovascular disease, hepatocellular carcinoma, end-stage liver disease. The severity of these complications is proportional to the severity of the histological stage and grade of the liver disease.
Education of patients is crucial to obtain the best patient outcomes. Some of the resources include:
The incidence and prevalence of non-alcoholic fatty liver disease are rising and will continue to rise due to increasing obesity and lifestyle changes. The management of NAFLD will require a multidisciplinary team that consists of a primary care physician, nurse practitioner, hepatologist or gastroenterologist, nutritionist, endocrinologist, bariatrician. Primary prevention with adequate management of metabolic derangement is essential to prevent the rising incidence of NAFLD and its associated complications. To lower the risk of heart disease, patients should be urged to reduce body weight, discontinue smoking, eat a healthy diet and participate in regular exercise.
Management of NAFLD should is optimal with an interprofessional health care team that includes physicians, specialists, specialty-trained nurses, and where appropriate, pharmacists. These different disciplines need to engage in open communication about the patient to assure the best possible outcomes.
We are looking for contributors to author, edit, and peer review our vast library of review articles and multiple choice questions. In as little as 2-3 hours you can make a significant contribution to your specialty. In return for a small amount of your time, you will receive free access to all content and you will be published as an author or editor in eBooks, apps, online CME/CE activities, and an online Learning Management System for students, teachers, and program directors that allows access to review materials in over 500 specialties.
This is an academic project designed to provide inexpensive peer-reviewed Apps, eBooks, and very soon an online CME/CE system to help students identify weaknesses and improve knowledge. We would like you to consider being an author or editor. Please click here to learn more. Thank you for you for your interest, the StatPearls Publishing Editorial Team.
Click Your Answer Below
Would you like to access teaching points and more information on this topic?
Improve Content - Become an Author or Editor and get free access to the entire database, free eBooks, as well as free CME/CE as it becomes available. If interested, please click on "Sign Up" to register.
Purchase- Want immediate access to questions, answers, and teaching points? They can be purchased above at Apps and eBooks.
|Milić S,Stimac D, Nonalcoholic fatty liver disease/steatohepatitis: epidemiology, pathogenesis, clinical presentation and treatment. Digestive diseases (Basel, Switzerland). 2012; [PubMed]|
|Lee YH,Cho Y,Lee BW,Park CY,Lee DH,Cha BS,Rhee EJ, Nonalcoholic Fatty Liver Disease in Diabetes. Part I: Epidemiology and Diagnosis. Diabetes [PubMed]|
|Aguilera-Méndez A, Nonalcoholic hepatic steatosis: a silent disease Revista medica del Instituto Mexicano del Seguro Social. 2019 Mar 15; [PubMed]|
|Frediani JK,Naioti EA,Vos MB,Figueroa J,Marsit CJ,Welsh JA, Arsenic exposure and risk of nonalcoholic fatty liver disease (NAFLD) among U.S. adolescents and adults: an association modified by race/ethnicity, NHANES 2005-2014. Environmental health : a global access science source. 2018 Jan 15; [PubMed]|
|Saokaew S,Kanchanasuwan S,Apisarnthanarak P,Charoensak A,Charatcharoenwitthaya P,Phisalprapa P,Chaiyakunapruk N, Clinical risk scoring for predicting non-alcoholic fatty liver disease in metabolic syndrome patients (NAFLD-MS score). Liver international : official journal of the International Association for the Study of the Liver. 2017 Oct; [PubMed]|
|Bellentani S,Scaglioni F,Marino M,Bedogni G, Epidemiology of non-alcoholic fatty liver disease. Digestive diseases (Basel, Switzerland). 2010; [PubMed]|
|Khoonsari M,Mohammad Hosseini Azar M,Ghavam R,Hatami K,Asobar M,Gholami A,Rajabi A,Safarnezhad Tameshkel F,Amirkalali B,Sohrabi M, Clinical Manifestations and Diagnosis of Nonalcoholic Fatty Liver Disease. Iranian journal of pathology. 2017 Spring; [PubMed]|
|Basaranoglu M,Neuschwander-Tetri BA, Nonalcoholic Fatty Liver Disease: Clinical Features and Pathogenesis. Gastroenterology [PubMed]|
|Del Campo JA,Gallego-Durán R,Gallego P,Grande L, Genetic and Epigenetic Regulation in Nonalcoholic Fatty Liver Disease (NAFLD). International journal of molecular sciences. 2018 Mar 19; [PubMed]|
|Takahashi Y,Fukusato T, Histopathology of nonalcoholic fatty liver disease/nonalcoholic steatohepatitis. World journal of gastroenterology. 2014 Nov 14; [PubMed]|
|Brunt EM,Tiniakos DG, Histopathology of nonalcoholic fatty liver disease. World journal of gastroenterology. 2010 Nov 14; [PubMed]|
|Brown GT,Kleiner DE, Histopathology of nonalcoholic fatty liver disease and nonalcoholic steatohepatitis. Metabolism: clinical and experimental. 2016 Aug; [PubMed]|
|Obika M,Noguchi H, Diagnosis and evaluation of nonalcoholic fatty liver disease. Experimental diabetes research. 2012; [PubMed]|
|Ekstedt M,Franzén LE,Mathiesen UL,Thorelius L,Holmqvist M,Bodemar G,Kechagias S, Long-term follow-up of patients with NAFLD and elevated liver enzymes. Hepatology (Baltimore, Md.). 2006 Oct; [PubMed]|
|White DL,Kanwal F,El-Serag HB, Association between nonalcoholic fatty liver disease and risk for hepatocellular cancer, based on systematic review. Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association. 2012 Dec; [PubMed]|
|Machado MV,Cortez-Pinto H, Non-alcoholic fatty liver disease: what the clinician needs to know. World journal of gastroenterology. 2014 Sep 28; [PubMed]|
|Brunt EM,Janney CG,Di Bisceglie AM,Neuschwander-Tetri BA,Bacon BR, Nonalcoholic steatohepatitis: a proposal for grading and staging the histological lesions. The American journal of gastroenterology. 1999 Sep [PubMed]|
The intent of StatPearls is to provide practice questions and explanations to assist you in identifying and resolving knowledge deficits. These questions and explanations are not intended to be a source of the knowledge base of all of medicine, nor is it intended to be a board or certification review of Lab-Clinical Laboratory Scientist (MT). The authors or editors do not warrant the information is complete or accurate. The reader is encouraged to verify each answer and explanation in several references. All drug indications and dosages should be verified before administration.
StatPearls offers the most comprehensive database of free multiple-choice questions with explanations and short review chapters ever developed. This system helps physicians, medical students, dentists, nurses, pharmacists, and allied health professionals identify education deficits and learn new concepts. StatPearls is not a board or certification review system for Lab-Clinical Laboratory Scientist (MT), it is a learning system that you can use to help improve your knowledge base of medicine for life-long learning. StatPearls will help you identify your weaknesses so that when you are ready to study for a board or certification exam in Lab-Clinical Laboratory Scientist (MT), you will already be prepared.
Our content is updated continuously through a multi-step peer review process that will help you be prepared and review for a thorough knowledge of Lab-Clinical Laboratory Scientist (MT). When it is time for the Lab-Clinical Laboratory Scientist (MT) board and certification exam, you will already be ready. Besides online study quizzes, we also publish our peer-reviewed content in eBooks and mobile Apps. We also offer inexpensive CME/CE, so our content can be used to attain education credits while you study Lab-Clinical Laboratory Scientist (MT).